Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding episodes and perioperative prophylaxis in patients with specific clotting disorders. It is used under medical supervision to replace missing clotting proteins.

• Treatment of acute bleeding episodes in hemophilia A patients.
• Surgical or invasive procedure prophylaxis for hemophilia A.
• Management of bleeding in von Willebrand disease types 1, 2, and 3.
• Long‑term prophylaxis to reduce frequency of spontaneous bleeds in severe hemophilia A.
• Adjunct therapy when other factor concentrates are unavailable or contraindicated.

Side effects of Haemate P may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Headache or mild dizziness.
• Fever or chills.
• Injection site pain, redness, or swelling.
• Nausea or mild gastrointestinal discomfort.
• Transient increase in blood pressure.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Thromboembolic events such as deep vein thrombosis.
• Hemolysis or renal impairment.
• Severe hypotension or shock.

Healthcare providers should assess individual risk factors before initiating Haemate P therapy. Monitoring and patient education are essential.

• Screen for a history of inhibitors to factor VIII before treatment.
• Use caution in patients with cardiovascular disease or a history of thrombosis.
• Monitor for signs of allergic reactions during infusion.
• Adjust dosing in patients with renal or hepatic impairment as clinically indicated.
• Ensure proper aseptic technique to prevent contamination.
• Educate patients on recognizing symptoms of inhibitor development and thrombosis.

Haemate P may interact with other medications that affect hemostasis or immune response. Review patient medication lists carefully.

Avoid

• Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) without specialist guidance.
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Immunosuppressive therapies that may alter inhibitor formation.
• Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement.
• Other plasma‑derived products that could increase viral transmission risk.
• Vaccinations administered shortly before or after infusion.